EU/3/19/2165

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2165) was granted by the European Commission to Dipharma B.V., the Netherlands, for sodium benzoate, sodium phenylacetate for the treatment of citrullinaemia type 1.

Key facts

Active substance
Sodium benzoate, sodium phenylacetate
Disease / condition
Treatment of citrullinaemia type 1
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2165

Sponsor's contact details

Dipharma B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
Netherlands
Tel. +41 9160 11713
E-mail: regulatory@dipharma-group.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating